DuraStat
Private Company
Funding information not available
Overview
DuraStat is a private, commercial-stage medical device company tackling a significant unmet need in spine surgery: the repair of incidental durotomies. Its flagship product, the DuraStat device, is a handheld instrument that automates and simplifies the technically challenging process of suturing the delicate dura mater, aiming to reduce operative time and improve repair quality to prevent costly CSF leaks. Founded in 2017 by surgeons and backed by an experienced board, the company is now focused on commercial adoption by hospitals and surgeons in the United States. DuraStat's value proposition centers on improving patient outcomes while reducing the economic burden of surgical complications on the healthcare system.
Technology Platform
A handheld surgical device that automates and simplifies sutured dural repair. It features a pre-loaded curved needle and suture within a curved tip, with button-activated needle deployment designed to eliminate the need for wrist supination, consolidate procedural steps, and improve precision in confined surgical fields.
Opportunities
Risk Factors
Competitive Landscape
DuraStat competes in the dural repair market against established alternatives including fibrin-based sealants (e.g., Tisseel, Evicel), collagen matrix patches (e.g., DuraGen), and traditional manual suturing techniques. Its key differentiation is enabling a superior sutured closure with greater ease and speed, rather than offering a passive sealant. It must convince surgeons that its mechanical approach yields better long-term outcomes than simpler, often cheaper, adhesive options.